CAD CAM

Main information

  • Trade name:
  • CAD/CAM unit, dental, chairside
  • Class:
  • Class 1
  • Medicine domain:
  • Humans
  • Medicine type:
  • Medical device

Documents

Localization

  • Available in:
  • CAD/CAM unit, dental, chairside
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 217606
  • Last update:
  • 09-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

217606

Carestream Health Australia Pty Ltd - CAD/CAM unit, dental, chairside

ARTG entry for

Medical Device Included Class 1

Sponsor

Carestream Health Australia Pty Ltd

Postal Address

Level 3 / 176 Wellington Parade,East Melbourne, VIC, 3002

Australia

ARTG Start Date

21/11/2013

Product category

Medical Device Class 1

Status

Active

Approval area

Medical Devices

Conditions

- The inclusion of the kind of device in the ARTG is subject to compliance with all conditions placed or imposed on the ARTG entry. Refer Part 4-5,

Division 2 (Conditions) of the Therapeutic Goods Act 1989 and Part 5, Division 5.2 (Conditions) of the Therapeutic Goods (Medical Devices) Regulations

2002 for relevant information.

- Breaching conditions of the inclusion related to the device of the kind may lead to suspension or cancellation of the ARTG entry; may be a criminal

offence; and civil penalties may apply.

Manufacturers

Name

Address

Carestream Health Inc

150 Verona Street

Rochester, New York, 14608

United States Of America

Products

1. CAD/CAM unit, dental, chairside

Product Type

Single Device Product

Effective date

21/11/2013

GMDN

38597 CAD/CAM unit, dental, chairside

Intended purpose

An intraoral scanner used to take a digital 2D and 3D impression of the patient's mouth/teeth. For

computer-aided design (CAD) and manufacturing/production (CAM) of dental restorations.

Specific Conditions

No Specific Conditions included on Record

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 10.11.2017 at 01:41:45 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

1-3-2019

La FDA agrega un Recuadro de advertencia por el aumento en el riesgo de muerte con el medicamento para la gota Uloric (febuxostat)

La FDA agrega un Recuadro de advertencia por el aumento en el riesgo de muerte con el medicamento para la gota Uloric (febuxostat)

La FDA agrega un Recuadro de advertencia por el aumento en el riesgo de muerte con el medicamento para la gota Uloric (febuxostat)

FDA - U.S. Food and Drug Administration

7-12-2018

La FDA advierte que los síntomas de una afección grave que afecta las células sanguíneas no son reconocidos con el medicamento para la leucemia Idhifa (enasidenib)

La FDA advierte que los síntomas de una afección grave que afecta las células sanguíneas no son reconocidos con el medicamento para la leucemia Idhifa (enasidenib)

La FDA advierte que los síntomas de una afección grave que afecta las células sanguíneas no son reconocidos con el medicamento para la leucemia Idhifa (enasidenib)

FDA - U.S. Food and Drug Administration

7-12-2018

La FDA advierte acerca de los riesgos graves de accidente cerebrovascular y desgarro de las paredes de los vasos sanguíneos con el medicamento para la esclerosis múltiple Lemtrada (alemtuzumab)

La FDA advierte acerca de los riesgos graves de accidente cerebrovascular y desgarro de las paredes de los vasos sanguíneos con el medicamento para la esclerosis múltiple Lemtrada (alemtuzumab)

La FDA advierte acerca de los riesgos graves de accidente cerebrovascular y desgarro de las paredes de los vasos sanguíneos con el medicamento para la esclerosis múltiple Lemtrada (alemtuzumab)

FDA - U.S. Food and Drug Administration

27-9-2018

Mauna Loa Macadamia Nut Corporation Voluntarily Recalls

Mauna Loa Macadamia Nut Corporation Voluntarily Recalls

Mauna Loa Macadamia Nut Corporation is voluntarily recalling all of its products produced at the Keaau facility between Sept. 6 - 21, 2018 due to a potential contamination of Escherichia coli (E. coli). The recall was initiated due to E. coli being detected in the well water and distribution system that supplies the firm's operations. No illnesses related to the water have been reported to the state.

FDA - U.S. Food and Drug Administration

14-9-2018

Pending EC decision:  Inflacam, meloxicam, Opinion date: 13-Sep-2018

Pending EC decision: Inflacam, meloxicam, Opinion date: 13-Sep-2018

Europe - EMA - European Medicines Agency

14-9-2018

Pending EC decision:  Rheumocam, meloxicam, Opinion date: 13-Sep-2018

Pending EC decision: Rheumocam, meloxicam, Opinion date: 13-Sep-2018

Europe - EMA - European Medicines Agency

19-3-2019

Loxicom (Norbrook Laboratories (Ireland) Limited)

Loxicom (Norbrook Laboratories (Ireland) Limited)

Loxicom (Active substance: Meloxicam) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2179 of Tue, 19 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/141/T/32

Europe -DG Health and Food Safety

5-3-2019

Melosus (CP-Pharma Handelsgesellschaft mbH)

Melosus (CP-Pharma Handelsgesellschaft mbH)

Melosus (Active substance: Meloxicam) - Centralised - 2-Monthly update - Commission Decision (2019)1824 of Tue, 05 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/2001/IB/07

Europe -DG Health and Food Safety

25-1-2019

Loxicom (Norbrook Laboratories Ltd)

Loxicom (Norbrook Laboratories Ltd)

Loxicom (Active substance: Meloxicam) - Centralised - Renewal - Commission Decision (2019)671 of Fri, 25 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/141/R/31

Europe -DG Health and Food Safety

15-1-2019

Meloxidyl (Ceva SantE Animale)

Meloxidyl (Ceva SantE Animale)

Meloxidyl (Active substance: Meloxicam) - Centralised - Yearly update - Commission Decision (2019)210 of Tue, 15 Jan 2019

Europe -DG Health and Food Safety

29-11-2018

Inflacam (Chanelle Pharmaceuticals Manufacturing Limited)

Inflacam (Chanelle Pharmaceuticals Manufacturing Limited)

Inflacam (Active substance: Meloxicam) - Centralised - Variation - Commission Decision (2018)8036 of Thu, 29 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2497/X/15

Europe -DG Health and Food Safety

21-11-2018

Rheumocam (Chanelle Pharmaceuticals Manufacturing Limited)

Rheumocam (Chanelle Pharmaceuticals Manufacturing Limited)

Rheumocam (Active substance: Meloxicam) - Centralised - Variation - Commission Decision (2018)7841 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/121/X/22

Europe -DG Health and Food Safety

19-10-2018

Recocam (Bimeda Animal Health Limited)

Recocam (Bimeda Animal Health Limited)

Recocam (Active substance: Meloxicam) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6954 of Fri, 19 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2247/T/10

Europe -DG Health and Food Safety

24-9-2018

Mektovi (Pierre Fabre MEdicament)

Mektovi (Pierre Fabre MEdicament)

Mektovi (Active substance: binimetinib) - Centralised - Authorisation - Commission Decision (2018)6217 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/004579/0000

Europe -DG Health and Food Safety

24-9-2018

Braftovi (Pierre Fabre MEdicament)

Braftovi (Pierre Fabre MEdicament)

Braftovi (Active substance: encorafenib) - Centralised - Authorisation - Commission Decision (2018)6216 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/004580/0000

Europe -DG Health and Food Safety

7-8-2018

Novem (Boehringer Ingelheim Vetmedica GmbH)

Novem (Boehringer Ingelheim Vetmedica GmbH)

Novem (Active substance: Meloxicam) - Centralised - Yearly update - Commission Decision (2018)5413 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

29-5-2018

Meloxivet (Eli Lilly and Company Limited)

Meloxivet (Eli Lilly and Company Limited)

Meloxivet (Active substance: Meloxicam) - Centralised - Withdrawal - Commission Decision (2018)3408 of Tue, 29 May 2018

Europe -DG Health and Food Safety